Inactive Instrument

News TearLab Corporation

Stocks

Medical Equipment, Supplies & Distribution

All News

24-07-22	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
21-12-09	TearLab Corporation Announces Board Appointments	CI
21-12-09	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
21-11-09	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
21-09-16	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
20-07-28	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
20-07-09	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-07-08	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
20-07-08	TearLab Corporation to Seek Acquisitions	CI
20-06-26	TearLab: 1Q Earnings Snapshot	AQ
20-06-26	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-06-26	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
20-06-08	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
20-05-29	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ
20-05-13	TEARLAB CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
20-05-12	TEARLAB CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
20-05-11	TEARLAB CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
20-05-11	TearLab Corporation Announces Board Appointments	CI
20-05-11	TEARLAB CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-05-11	Tearlab Mulls Inorganic Growth Opportunities	CI
20-05-11	TearLab : Announces Acquisition By Accelmed Partners And Related $25 Million Investment	PR
20-05-10	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
20-05-10	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI
20-05-07	TEARLAB CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-05-07	TearLab Corporation Confirms Merger Discussions	GL